Abstracts Archive - Page 815 of 2607 - ACR Meeting Abstracts

Abstract Number: 1648 • ACR Convergence 2021
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
Dylan Bergstedt¹, Ryan Peterson², Marie Feser¹, LauraKay Moss¹, Geoffrey Thiele³, Ted Mikuls³, Jess Edison⁴, V. Michael Holers¹ and Kevin Deane⁵, ¹University of Colorado Denver, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³University of Nebraska Medical Center, Omaha, NE, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
Abstract Number: 1649 • ACR Convergence 2021
Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder
Tomohiro Kameda¹, Shusaku Nakashima¹, Hiromi Shimada¹, Risa Wakiya¹, Mai Fahmy Mansour¹, Mikiya Kato¹, Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹, Norimitsu Kadowaki¹ and Hiroaki Dobashi², ¹Kagawa University, Takamatsu, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Japan
Background/Purpose: Methotrexate associated lymphoproliferative disorder (MTX-LPD) has various histological types from benign and malignant. Some MTX-LPDs spontaneously regress after discontinuation of MTX, even though they…
Abstract Number: 1650 • ACR Convergence 2021
Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis
Paolo Massimo Buscema¹, Giulia Massini², Francesca Della Torre², Masoud Asadi-Zeydabadi³, Colin O'Donnell⁴, Francis Newman⁵, Randall Tagg³, Weldon Lodwick⁵, Christopher Collora⁴, Marie Feser⁴, LauraKay Moss⁴, William Robinson⁶, Geoffrey Thiele⁷, Ted Mikuls⁷, Jess Edison⁸, V. Michael Holers⁴ and Kevin Deane⁹, ¹Semeion Research Center of Sciences of Communication; University of Colorado Denver Department of Mathematical and Statistical Sciences, Rome, Italy, ²Semeion Research Center of Sciences of Communication, Rome, Italy, ³University of Colorado Denver Department of Physics, Denver, CO, ⁴University of Colorado Denver, Aurora, CO, ⁵University of Colorado Denver Department of Mathematical and Statistical Sciences, Denver, CO, ⁶Stanford University, Palo Alto, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations of antibodies to citrullinated protein antibodies (ACPA), rheumatoid factor (RF), and…
Abstract Number: 1651 • ACR Convergence 2021
Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis
Salina Haville¹, Jennifer Seifert¹, Saman Barzideh¹, LauraKay Moss¹, Navin Rao², Alyssa Johnsen³, Jane Buckner⁴, Eddie James⁵, Sylvia Posso⁴, Gary Firestein⁶, David Boyle⁷, William Robinson⁸, V. Michael Holers⁹ and Kevin Deane¹⁰, ¹University of Colorado Denver, Aurora, CO, ²Janssen R&D, Spring House, PA, ³Janssen R&D, Princeton Junction, NJ, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Monroe, WA, ⁶University of California San Diego, San Diego, CA, ⁷University of California San Diego, La Jolla, CA, ⁸Stanford University, Palo Alto, CA, ⁹University of Colorado, Denver, CO, ¹⁰University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period definable as elevations of antibodies to citrullinated protein antibodies (ACPA) before clinically-apparent inflammatory arthritis (IA). ACPA elevations…
Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 1653 • ACR Convergence 2021
Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis
Jon Giles¹, Joan Bathon², Hadil Zureigat³ and Ahmed Tawakol⁴, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²Columbia University, New York, NY, ³Harvard University, Boston, MA, ⁴Harvard University/Massachusetts General Hospital, Boston, MA
Background/Purpose: Subcutaneous adipose tissue (SAT) from people with RA contains more macrophages and expresses higher levels of cytokines, chemokines, and other inflammatory mediators compared with…
Abstract Number: 1654 • ACR Convergence 2021
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
Abstract Number: 1655 • ACR Convergence 2021
Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
Lucia Cristina Dominguez Casas¹, Paz Rodriguez-Cundin², Trinidad Dierssen³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³University of Cantabria, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, Santadner, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed…
Abstract Number: 1656 • ACR Convergence 2021
Women with Rheumatoid Arthritis Have More Multimorbidity Than Men in a Large Nationwide US Study
Hayley Dykhoff¹, Elena Myasoedova¹, Madeline Peterson¹, John Davis¹, Vanessa Kronzer¹, Caitrin Coffey¹, Tina Gunderson¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with RA have an increased burden of multimorbidity. Although many comorbidities vary by sex, sex differences in multimorbidity among individuals with RA have…
Abstract Number: 1657 • ACR Convergence 2021
Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis
Cynthia Crowson¹, Tina Gunderson², Elena Myasoedova², Elizabeth Atkinson², Vanessa Kronzer², Caitrin Coffey² and John Davis², ¹Mayo Clinic, Eyota, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Multimorbidity is common in patients with rheumatoid arthritis (RA), and it is associated with poor outcomes. The literature on multimorbidity suffers from numerous definitions…
Abstract Number: 1658 • ACR Convergence 2021
Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis
Katherine Liao¹, Thany Seyok¹ and Lisa Cannon-Albright², ¹Brigham and Women's Hospital, Boston, MA, ²University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Autoimmune conditions appear to cluster in families, as may be expected by shared genetic risk factors in conditions such as rheumatoid arthritis (RA), autoimmune…
Abstract Number: 1659 • ACR Convergence 2021
Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database
jens Pedersen¹, Lei Wang², Alma Pedersen², Kjeld Andersen³, Claus Sørensen³ and Torkell Ellingsen⁴, ¹Department of Medicine M, Section of Rheumatology, Svendborg Hospital, Odense University Hospital, Svendborg, Denmark, Odense, Denmark, ²Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Mental Health, Odense, Odense, Denmark, ⁴Rheumatology Research Unit, Department of Rheumatology C, Odense University Hospital, Odense, Denmark
Background/Purpose: Depression occurs with a prevalence of about 17% (95% confidence interval (CI): 10-24) in patients with RA (1) and both disorders may share common…
Abstract Number: 1660 • ACR Convergence 2021
Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
So Hye Nam¹, Min-Ju Kim², Ye-Jee kim², Soo Min Ahn², Seokchan Hong³, Chang-Keun Lee², Bin Yoo³, Ji Seon Oh⁴ and Yong-Gil Kim², ¹Uijeongbu Eulji Medical Center, Uijeongbu, Gyeonggi-do, Republic of Korea, ²Asan Medical Center, Seoul, Republic of Korea, ³Asan Medical Center, Seoul, South Korea, ⁴Asan Medical Center, Ulsan, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects glucose metabolism, mainly insulin resistance, which can lead to diabetes mellitus (DM). Although there…
Abstract Number: 1661 • ACR Convergence 2021
Sex-Stratified Patterns of Multimorbidity at RA Onset and Associated Longitudinal Impacts on Disability Over the First Year Follow Up: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Susan Bartlett², Marie-France Valois², Louis Bessette³, Gilles Boire⁴, Glen Hazlewood⁵, Edward Keystone⁶, Janet Pope⁷, Carter Thorne⁸, Diane Tin⁸ and Vivian Bykerk⁹, ¹Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Chronic disease multimorbidity (MM) is prevalent in RA. As MM can vary in complexity and different combinations of chronic conditions may have different physical…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].